Mulai
agilon health, inc.
Pembelian

Agilon Health | AGL | Long at $2.24

Oleh WorthlessViews
Agilon Health AGL

Pros:
  • Revenue consistently grew from 2019 ($794 million) to 2023 ($4.3 billion) and through three quarters of 2024 ($5.6 billion). Expected to reach $8.7 billion by 2027.
  • Current debt-to-equity ratio 0.06 (very low)
  • Sufficient cash reserves to fund operations and strategic initiatives
  • Strong membership growth (525,000 as of Q3 2024, a 37% year-over-year increase)
  • Recent insider buying ($2 - $3) and awarding of options


Cons:
  • Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
  • No dividend


Targets (into 2027):
  1. $2.72
  2. $4.00
  3. $5.00
  4. $7.00
  5. $11.50
  6. $16.00
agilonagilonhealthAGLGrowthhealthcarehealthcarestocksSupport and ResistanceTrend Lines
WorthlessViews
Juga di:

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.